Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$5.64
-AU$0.02(-0.35%)
At close: 4:00 PM EDT
AU$5.64
-AU$0.02(-0.35%)
Day’s Range― - ―
52-Week RangeAU$1.90 - AU$6.49
Previous CloseN/A
Volume465.77K
Average Volume (3M)878.02K
Market Cap
AU$780.19M
Enterprise ValueAU$920.15
Total Cash (Recent Filing)AU$74.17M
Total Debt (Recent Filing)AU$247.00K
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Mar 02, 2027EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding163,220,280
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio6.46
Price to Book (P/B)11.56
Price to Sales (P/S)32321.70
P/FCF Ratio-56.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.75Price Target Upside19.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)AU$9.23M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt limits near-term solvency risk and interest burden, giving Artrya greater flexibility to fund product development and commercial expansion without substantial creditor claims on future cash flows.
Growing U.S. Commercial AdoptionDeployment across established U.S. health systems provides evidence that Salix is moving beyond development into clinical workflows, supporting a scalable base for recurring subscriptions and fee-per-scan revenue.
Expanded Product PipelineAdding validated coronary-flow analysis could broaden Salix’s clinical scope and strengthen its positioning as an integrated cardiac imaging platform, potentially improving adoption and reimbursement opportunities over time.
Bears Say
Minimal Commercial RevenueThe extremely small revenue base shows that commercialization remains at an early stage. Artrya has yet to demonstrate sufficient customer scale or recurring sales to support its operating cost structure sustainably.
Persistent Cash BurnHeavy recurring cash outflows indicate that the operating business is not self-funding. Continued investment in development and commercialization may require additional capital before meaningful cash generation is achieved.
Widening Losses And Funding DependenceRising losses alongside a sharp increase in equity suggests reliance on shareholder funding to sustain operations. This can pressure future returns and create dilution risk if commercial progress remains slower than planned.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$1.90 and its highest was AU$6.49 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$780.19M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Mar 02, 2027 which is in 185 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.089 earnings per share for the quarter, missing the consensus estimate of -AU$0.055 by -AU$0.034.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.08.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 163,220,280 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.089 in its last earnings report, missing expectations of -AU$0.055. Following the earnings report the stock price went up 4.393%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.75 (19.68% Upside)
AU$6.75 (19.68% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$4.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
260.49%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.75
▲(19.68% Upside)
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
Alcidion Group Limited
―







